Tango Therapeutics Inc
NASDAQ:TNGX
Operating Margin
Tango Therapeutics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
800.5m USD |
-647%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
364.7B USD |
31%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
157.9B USD |
31%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
146.8B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
100.1B USD |
39%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
131.4B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
61.4B USD |
29%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
59.7B USD |
-7%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Tango Therapeutics Inc
Glance View
Tango Therapeutics, Inc. operates as a biotechnology company that engages in discovering and delivering precision cancer medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 91 full-time employees. The company went IPO on 2020-09-03. The firm is engaged in the discovery and development of drugs at tumor suppressor gene loss in patients with unmet medical need. The Company’s product candidates include TNG908 and ubiquitin-specific protease 1 (USP1). Its TNG908, is a potent, selective, synthetic lethal, small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), which is designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. The MTAP-deletion occurs in all human tumors, including cancers with unmet need, such as squamous cell lung, esophageal and bladder cancer. The Company’s USP1, is a synthetic lethal that target for BRCA1-mutant breast, ovarian and prostate cancer. The USP1 treats a patient population for poly (ADP-ribose) polymerase (PARP) inhibitors that are operative against cancers with BRCA1 and BRCA2 mutations.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Tango Therapeutics Inc's most recent financial statements, the company has Operating Margin of -647.3%.
You don't have any saved screeners yet